NEWS
- Clinical Development of ADC Drugs Targeting TROP-2
- PROTACs VS. Traditional Small Molecule Inhibitors
- Summary of PROTAC Degraders in Clinical Trials
- ADC Drugs: Some Challenges To Be Solved
- Trophoblast Glycoprotein (TPGB/5T4): A New Target For ADC Drugs
- Emerging drugs for the treatment of PNH
- Peptide PROTAC in Drug Development
- FGF21 agonist for MASH: Current Status
- Next-Generation mRNA-LNPs: Strategies to Reduce Anti-PEG Antibody Responses
- CD388, a Novel Drug Fc-Conjugate (DFC) to Prevent Influenza Infection
